Efficib (Sitagliptin/Metformin)

What Is Efficib and What Is It Used For?

Efficib is a prescription combination medicine containing sitagliptin and metformin hydrochloride, used to treat type 2 diabetes mellitus in adults. It is prescribed when diet, exercise, and metformin alone do not adequately control blood sugar, or for patients already taking both ingredients as separate tablets.

Efficib belongs to a class of medicines known as fixed-dose combination antidiabetic agents. It contains two active substances that work through different but complementary mechanisms to control blood glucose levels. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, sometimes called a gliptin, while metformin hydrochloride is a biguanide — one of the oldest and most widely used diabetes medicines in the world.

The combination of these two agents in a single tablet offers several advantages. First, it simplifies the treatment regimen by reducing the number of tablets a patient needs to take each day, which can significantly improve medication adherence. Second, the two active substances target different aspects of glucose metabolism, providing more comprehensive blood sugar control than either agent alone. Clinical studies have demonstrated that the sitagliptin/metformin combination provides statistically significant reductions in HbA1c (glycated haemoglobin) compared with metformin monotherapy.

Type 2 diabetes is a chronic metabolic condition affecting over 460 million people worldwide according to the International Diabetes Federation. It is characterised by insulin resistance (where the body's cells do not respond properly to insulin) and progressive beta-cell dysfunction (where the pancreas gradually produces less insulin). Left untreated or poorly controlled, type 2 diabetes can lead to serious complications including cardiovascular disease, kidney damage (diabetic nephropathy), nerve damage (diabetic neuropathy), and vision problems (diabetic retinopathy).

How Does Efficib Work?

Efficib's dual mechanism of action addresses multiple aspects of the complex pathophysiology of type 2 diabetes:

Sitagliptin (DPP-4 inhibitor): After eating, the gut releases hormones called incretins — primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones stimulate the pancreas to produce insulin and suppress the release of glucagon (a hormone that raises blood sugar). In healthy individuals, incretins are rapidly broken down by the enzyme DPP-4. Sitagliptin blocks this enzyme, allowing incretin levels to remain elevated for longer. Importantly, this insulin-stimulating effect is glucose-dependent, meaning it works primarily when blood sugar is elevated, which reduces the risk of hypoglycemia.

Metformin (biguanide): Metformin works through several complementary mechanisms. It primarily reduces the amount of glucose produced by the liver (hepatic gluconeogenesis), which is often abnormally elevated in type 2 diabetes. It also improves insulin sensitivity in peripheral tissues, particularly skeletal muscle, allowing cells to take up glucose more effectively. Additionally, metformin delays the absorption of glucose from the gastrointestinal tract. Unlike sulfonylureas, metformin does not stimulate insulin secretion directly and therefore carries a low risk of causing hypoglycemia when used alone.

When Is Efficib Prescribed?

According to the European Medicines Agency (EMA) approved indications, Efficib is prescribed in the following situations:

• As an add-on to metformin: For patients whose blood sugar is inadequately controlled with the maximum tolerated dose of metformin alone, along with diet and exercise
• In combination with a sulfonylurea: When dual therapy with metformin and a sulfonylurea (with diet and exercise) does not provide adequate glycemic control
• In combination with insulin: As an adjunct to insulin when insulin plus metformin alone do not provide adequate control
• As a replacement: For patients already being treated with sitagliptin and metformin as separate tablets, to simplify their regimen

What Should You Know Before Taking Efficib?

Before taking Efficib, your doctor must assess your kidney function, liver health, and medical history. Efficib must not be used in severe renal impairment (eGFR <30 mL/min), diabetic ketoacidosis, or conditions that increase the risk of lactic acidosis. Special caution is required before procedures using iodinated contrast media.

Efficib is a powerful combination medication, and there are several important factors your healthcare provider must consider before prescribing it. Understanding these precautions helps ensure the medication is used safely and effectively.

Contraindications

Efficib must not be used in the following situations:

• Hypersensitivity: Known allergy to sitagliptin, metformin, or any of the excipients in the tablet
• Severe renal impairment: Estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m²
• Diabetic ketoacidosis: A dangerous condition where the body produces excess blood acids (ketones)
• Diabetic pre-coma: Severe uncontrolled diabetes requiring emergency insulin treatment
• Conditions predisposing to lactic acidosis: Including acute or chronic metabolic acidosis, severe dehydration, severe infection, shock, or acute heart failure with tissue hypoperfusion
• Hepatic impairment: Significant liver disease, as this increases the risk of lactic acidosis due to impaired lactate clearance
• Acute alcohol intoxication: Excessive alcohol consumption, particularly binge drinking, increases lactic acidosis risk

Warnings and Precautions

Several important warnings apply to patients taking Efficib. Your healthcare provider should discuss these with you before initiating treatment:

Lactic acidosis: This is a rare but extremely serious metabolic complication that can occur due to metformin accumulation. It has a high mortality rate if untreated. The risk is increased in patients with renal impairment, uncontrolled diabetes, prolonged fasting, excessive alcohol intake, hepatic insufficiency, or any condition associated with tissue hypoxia (such as acute heart failure or recent myocardial infarction). Symptoms include muscle cramps, abdominal pain, rapid or difficult breathing, unusual tiredness, and feeling cold. If lactic acidosis is suspected, Efficib must be discontinued immediately and the patient hospitalised.

Kidney function monitoring: Because metformin is eliminated by the kidneys, renal function must be assessed before starting Efficib and at regular intervals thereafter — at least annually in patients with normal renal function, and at least two to four times per year in patients with eGFR at or approaching 45 mL/min/1.73 m² and in elderly patients. If eGFR falls below 30 mL/min, Efficib must be discontinued.

Iodinated contrast procedures: Metformin must be stopped at the time of, or prior to, imaging procedures involving iodinated contrast agents (such as CT scans with contrast). The metformin-containing product should not be restarted until at least 48 hours after the procedure, and only after renal function has been re-evaluated and found to be stable. Iodinated contrast can cause acute kidney injury, which in turn could lead to metformin accumulation and lactic acidosis.

Surgery: Efficib must be discontinued 48 hours before elective surgery under general, spinal, or epidural anaesthesia. It may be restarted no earlier than 48 hours after surgery and only after oral intake has resumed and renal function is stable.

Pancreatitis: Cases of acute pancreatitis, including fatal and non-fatal haemorrhagic or necrotising pancreatitis, have been reported in patients taking sitagliptin. Patients should be informed of the characteristic symptoms of acute pancreatitis: persistent, severe abdominal pain that may radiate to the back. If pancreatitis is suspected, Efficib should be discontinued. If confirmed, Efficib should not be restarted.

Hypoglycemia when combined with other drugs: While Efficib alone carries a low risk of hypoglycemia, the risk increases significantly when it is used in combination with a sulfonylurea or insulin. In these cases, a lower dose of the sulfonylurea or insulin may be needed to reduce hypoglycemia risk.

Pregnancy and Breastfeeding

There are limited data on the use of sitagliptin in pregnant women. Animal studies with metformin do not indicate harmful effects on pregnancy, embryonal or foetal development, parturition, or postnatal development. However, as a precautionary measure, Efficib is not recommended during pregnancy. Women who are planning to become pregnant or who become pregnant while taking Efficib should discuss with their healthcare provider about switching to insulin therapy for glycemic control during pregnancy, as recommended by most international diabetes guidelines including those from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Metformin is excreted in human breast milk. It is not known whether sitagliptin is excreted in human breast milk; however, animal studies show that sitagliptin is secreted in milk. A decision must therefore be made whether to discontinue breastfeeding or to discontinue Efficib, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.

How Does Efficib Interact with Other Drugs?

Efficib can interact with several medications. The most clinically significant interactions involve iodinated contrast agents, alcohol, insulin, sulfonylureas, and certain drugs that affect kidney function. Always inform your healthcare provider about all medications you are taking, including over-the-counter products and supplements.

Understanding drug interactions is critical for the safe and effective use of Efficib. Both active components — sitagliptin and metformin — have their own interaction profiles. Sitagliptin is primarily eliminated by the kidneys via active tubular secretion and, to a lesser extent, metabolised by CYP3A4 and CYP2C8 enzymes. Metformin is not metabolised by the liver and is eliminated unchanged by the kidneys through tubular secretion and glomerular filtration.

Major Interactions

The following interactions are considered clinically significant and may require dose adjustments, close monitoring, or avoidance:

Minor Interactions

The following interactions are generally less clinically significant but should still be noted:

This is not a complete list of drug interactions. Always tell your doctor, pharmacist, or other healthcare provider about all the medicines you take, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements. Do not start, stop, or change the dose of any medicine without your doctor's approval.

What Is the Correct Dosage of Efficib?

The dose of Efficib is individualised based on the patient's current therapy, effectiveness, and tolerability. The most common dose is 50 mg/850 mg or 50 mg/1000 mg twice daily with meals. The dose should be gradually increased to reduce gastrointestinal side effects from metformin.

Dosing of Efficib must always be individualised by the prescribing physician. The appropriate strength should be selected based on the patient's current antidiabetic regimen, efficacy goals, and tolerability. Efficib should always be taken with meals to reduce the gastrointestinal side effects associated with metformin.

Adults

Children

The safety and efficacy of Efficib in children and adolescents below 18 years of age have not been established. No data are available. Therefore, Efficib is not recommended for use in paediatric patients. The EMA and FDA have not approved sitagliptin/metformin combination tablets for use in children.

Elderly

No dose adjustment is required solely based on age. However, because kidney function naturally declines with age, renal function must be assessed more frequently in elderly patients. The metformin component of Efficib is substantially excreted by the kidney, and the risk of metformin-associated adverse effects (including lactic acidosis) is greater in patients with impaired renal function. Therefore, eGFR should be monitored regularly, and Efficib should be used with caution, particularly in patients aged 75 years and older. Dose adjustment may be necessary as renal function changes over time.

Renal Impairment

Kidney function directly impacts the safety of Efficib. The following guidelines apply based on estimated glomerular filtration rate:

• eGFR ≥ 60 mL/min: No dose adjustment required
• eGFR 45–59 mL/min: Maximum metformin dose is 1000 mg per day (i.e., Efficib 50 mg/500 mg twice daily if available, or careful selection of appropriate strength). More frequent renal monitoring recommended.
• eGFR 30–44 mL/min: Maximum metformin dose is 500 mg per day. Enhanced renal monitoring required (every 3–6 months).
• eGFR < 30 mL/min: Efficib is contraindicated

Missed Dose

If you forget to take a dose of Efficib, take it as soon as you remember — provided it is taken with a meal. If it is nearly time for your next scheduled dose, skip the missed dose and continue with your normal schedule. Do not take a double dose to make up for a forgotten dose, as this may increase the risk of side effects, particularly gastrointestinal symptoms from metformin and the potential for hypoglycemia.

Overdose

In the event of an overdose with Efficib, standard supportive measures should be initiated. Metformin overdose can lead to lactic acidosis, which is a medical emergency. Metformin is dialysable (clearance up to 170 mL/min under good haemodynamic conditions), so haemodialysis may be useful for removal of accumulated metformin in suspected overdose cases. Sitagliptin is modestly dialysable (approximately 13.5% removed over a 3–4 hour haemodialysis session). If overdose is suspected, contact your local poison control centre or emergency department immediately.

What Are the Side Effects of Efficib?

The most common side effects of Efficib are gastrointestinal in nature, primarily from the metformin component: nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. These often improve over time. Serious but rare side effects include lactic acidosis, pancreatitis, and severe allergic reactions.

Like all medicines, Efficib can cause side effects, although not everybody gets them. Most side effects are mild to moderate and tend to occur at the beginning of treatment, often improving as the body adjusts. The gastrointestinal side effects are mainly attributable to the metformin component and are frequently dose-related — this is why gradual dose titration is recommended.

Understanding the frequency classifications used in medicine helps put these side effects in perspective. Side effects are categorised by how often they occur in clinical trials:

Gastrointestinal Side Effects

The most frequently reported side effects of Efficib are gastrointestinal, primarily driven by the metformin component. These include nausea, vomiting, diarrhoea, abdominal pain, and reduced appetite. These symptoms typically occur at the start of therapy and often resolve spontaneously within a few weeks. Taking Efficib with meals significantly reduces their severity. If gastrointestinal symptoms persist despite taking the medication with food, your doctor may temporarily reduce the dose and increase it more slowly.

Vitamin B12 Deficiency

Long-term use of metformin has been associated with reduced absorption of vitamin B12. This occurs in approximately 5–10% of patients treated with metformin and may cause megaloblastic anaemia or peripheral neuropathy if severe. Periodic monitoring of vitamin B12 levels is recommended, particularly in patients with symptoms suggestive of deficiency, such as numbness, tingling in the extremities, or unusual fatigue. If vitamin B12 deficiency is detected, supplementation should be initiated.

When to Seek Immediate Medical Attention

Contact your doctor immediately or go to the nearest emergency department if you experience:

• Severe, persistent abdominal pain radiating to the back (possible pancreatitis)
• Rapid or laboured breathing, muscle cramps, unusual tiredness, stomach pain with nausea and vomiting, feeling cold (possible lactic acidosis)
• Swelling of the face, lips, tongue, or throat; difficulty breathing or swallowing (possible angioedema/anaphylaxis)
• Severe blistering of the skin, mouth, eyes, or genitals (possible Stevens-Johnson syndrome)
• Yellowing of the skin or eyes, dark urine (possible liver problems)

How Should You Store Efficib?

Store Efficib at room temperature below 25°C (77°F), in the original packaging to protect from moisture. Keep out of the reach and sight of children. Do not use after the expiry date printed on the packaging.

Proper storage of Efficib is important to maintain the medication's effectiveness and safety throughout its shelf life. Tablets should be stored in their original blister packaging or container to protect them from moisture and light. Like most oral medications, Efficib should be kept in a dry place at a controlled room temperature.

Do not store Efficib in the bathroom, near a kitchen sink, or in other damp or humid areas, as moisture can degrade the tablet coating and affect the stability of the active ingredients. Do not freeze the medication. If you notice any changes in the appearance of the tablets (such as discoloration, crumbling, or an unusual odour), do not use them and consult your pharmacist.

When travelling, keep Efficib in your carry-on luggage in its original packaging. Avoid leaving the medication in a car or other location where temperatures may exceed 25°C. Do not transfer the tablets to a different container unless advised by your pharmacist, as the original packaging provides the best protection.

Check the expiry date regularly. Do not use Efficib after the expiry date stated on the carton and blister after "EXP". The expiry date refers to the last day of that month. Unused or expired medicines should be returned to a pharmacy for proper disposal. Do not dispose of medicines via household waste or wastewater, as this can harm the environment.

What Does Efficib Contain?

Each Efficib 50 mg/850 mg tablet contains 50 mg sitagliptin (as sitagliptin phosphate monohydrate) and 850 mg metformin hydrochloride, along with excipients including microcrystalline cellulose, povidone, sodium stearyl fumarate, and a film-coating.

Active Ingredients

Each Efficib film-coated tablet contains two active substances:

• Sitagliptin 50 mg (as sitagliptin phosphate monohydrate) — a selective DPP-4 inhibitor that enhances the incretin system to improve glucose-dependent insulin secretion and suppress glucagon release
• Metformin hydrochloride 850 mg or 1000 mg — a biguanide that reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity in peripheral tissues

Inactive Ingredients (Excipients)

The inactive ingredients in Efficib include:

• Tablet core: Microcrystalline cellulose (E460), povidone K29/32 (E1201), sodium lauryl sulphate, sodium stearyl fumarate
• Film coating: Poly(vinyl alcohol), macrogol 3350, talc (E553b), titanium dioxide (E171), iron oxide red (E172), iron oxide black (E172)

If you have known allergies to any of these excipients, inform your healthcare provider before starting Efficib. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should note that Efficib does not contain lactose.